Harnessing the immune system to attack cancer

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and investors, we are well positioned in an exciting new era of immuno-oncology. Corvus is developing new drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it demonstrated favorable safety and pharmacologic properties. It recently entered cancer clinical trials.

The management team of Corvus includes inventors and scientists who played key roles in the development of Rituxan, Imbruvica and Zelboraf.